SCHEMBL4516489

SCHEMBL4516489

CCOC(=O)C(=CC(=O)O)Nc1ccc2[nH]c(=O)oc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 1/20 0.44
TSHR P16473 1/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
MAPKAPK2 P49137 4/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
GRIN3A Q8TCU5 1/20 0.42
NOS1 P29475 1/20 0.42
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALPL P05186 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4576197 0.84 MAPT (0.50) CREBBPTSHRKMT2AMEN1MAPKAPK2
SCHEMBL4516482 0.80 CREBBP (0.51) CREBBPKMT2AMEN1GRIN2DGRIN3B
SCHEMBL4516486 0.80 CREBBP (0.51) CREBBPKMT2AMEN1GRIN2DGRIN3B
SCHEMBL21460047 0.77 NOS1 (0.56) CREBBPMAPKAPK2GRIN2DGRIN3BGRIN1
SCHEMBL22424939 0.76 MEN1 (0.60) CREBBPTSHRKMT2AMEN1POLB
SCHEMBL31129257 0.73 CREBBP (0.61) CREBBPKMT2AMEN1MAPKAPK2GRIN2D
SCHEMBL9678808 0.73 CREBBP (0.56) CREBBPKMT2AGRIN2DGRIN3BGRIN1
SCHEMBL4621418 0.72 MAPT (0.64) KMT2AMEN1POLBTDP1MAPT
SCHEMBL4576717 0.72 GRIN2D (0.55) CREBBPGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL11618476 0.72 MAPT (0.43) TSHRKMT2ATDP1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012118-A1 Kynurenic Acid Amide Derivatives as Nr2b Receptor Antagoni RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2009-01-08 US disclosed
EP-1771436-A1 KYNURENIC ACID AMIDE DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS Richter Gedeon Vegy Szeti Gy R Rt. (HU) 2007-04-11 EP disclosed
WO-2006010967-A1 KYNURENIC ACID AMIDE DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS Richter Gedeon Vegyészeti Gyár Rt. (HU) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012118-A1 Kynurenic Acid Amide Derivatives as Nr2b Receptor Antagoni GRIN1, GRIN2A, GRIN2B CREBBP 2419/4885TSHR 1476/4885KMT2A 1319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.